These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30924705)

  • 1. Danaparoid is effective and safe for patients with obstetric antiphospholipid syndrome.
    Yoshihara H; Sugiura-Ogasawara M; Kitaori T; Katano K; Ozaki Y
    Mod Rheumatol; 2020 Mar; 30(2):332-337. PubMed ID: 30924705
    [No Abstract]   [Full Text] [Related]  

  • 2. An analysis of clinical outcomes of 91 pregnancies in 83 women treated with danaparoid (Orgaran).
    Magnani HN
    Thromb Res; 2010 Apr; 125(4):297-302. PubMed ID: 19656552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Danaparoid sodium.
    Acostamadiedo JM; Iyer UG; Owen J
    Expert Opin Pharmacother; 2000 May; 1(4):803-14. PubMed ID: 11249517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Danaparoid: a review of its use in thromboembolic and coagulation disorders.
    Ibbotson T; Perry CM
    Drugs; 2002; 62(15):2283-314. PubMed ID: 12381232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative review of the adverse effect profiles of heparins and heparinoids.
    Borris LC; Lassen MR
    Drug Saf; 1995 Jan; 12(1):26-31. PubMed ID: 7537967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
    Tardy-Poncet B; Tardy B; Reynaud J; Mahul P; Mismetti P; Mazet E; Guyotat D
    Chest; 1999 Jun; 115(6):1616-20. PubMed ID: 10378558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
    Wilde MI; Markham A
    Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.
    Magnani HN; Gallus A
    Thromb Haemost; 2006 Jun; 95(6):967-81. PubMed ID: 16732376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of 51 pregnancies with danaparoid because of heparin intolerance.
    Lindhoff-Last E; Kreutzenbeck HJ; Magnani HN
    Thromb Haemost; 2005 Jan; 93(1):63-9. PubMed ID: 15630492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Danaparoid in pregnancy in cases of heparin intolerance - use in 59 cases].
    Schindewolf M; Magnani HN; Lindhoff-Last E
    Hamostaseologie; 2007 May; 27(2):89-97. PubMed ID: 17479171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for bleeding during treatment of acute venous thromboembolism.
    Wester JP; de Valk HW; Nieuwenhuis HK; Brouwer CB; van der Graaf Y; Meuwissen OJ; Hart HC; Sixma JJ; Banga JD
    Thromb Haemost; 1996 Nov; 76(5):682-8. PubMed ID: 8950773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Is it safe and cost effective... Danaparoid (Orgaran) as an anticoagulant for mechanical autotransfusion with Cell Saver 5 (Hemonetics),Anaesthesist (2001) 50:26-31].
    Lorentz A
    Anaesthesist; 2001 Oct; 50(10):792. PubMed ID: 11702330
    [No Abstract]   [Full Text] [Related]  

  • 13. [Danaparoid sodium for dialysis in heparin-associated thrombocytopenia].
    Ben Ami R; Rachmimov R; Berliner S
    Harefuah; 1999 Mar; 136(5):361-4, 419. PubMed ID: 10914239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.
    de Valk HW; Banga JD; Wester JW; Brouwer CB; van Hessen MW; Meuwissen OJ; Hart HC; Sixma JJ; Nieuwenhuis HK
    Ann Intern Med; 1995 Jul; 123(1):1-9. PubMed ID: 7539233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s.
    Lubenow N; Warkentin TE; Greinacher A; Wessel A; Sloane DA; Krahn EL; Magnani HN
    Thromb Res; 2006; 117(5):507-15. PubMed ID: 15907979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical experiences with Danaparoid sodium. Measures to be taken in heparin-induced thrombocytopenia].
    Anaesthesist; 1998 Nov; 47(11 Suppl Massnahmen):1-4. PubMed ID: 9884734
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases.
    Fernandes P; Mayer R; MacDonald JL; Cleland AG; Hay-McKay C
    Perfusion; 2000 Nov; 15(6):531-9. PubMed ID: 11131218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical experience with Danaparoid-sodium: measures to be taken in heparin-induced thrombocytopenia].
    Chirurg; 1998 Nov; 69(11 Suppl Massnahme):1-4. PubMed ID: 9853175
    [No Abstract]   [Full Text] [Related]  

  • 19. Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses.
    Tardy B; Tardy-Poncet B; Viallon A; Piot M; Mazet E
    Thromb Haemost; 1998 Sep; 80(3):530. PubMed ID: 9759647
    [No Abstract]   [Full Text] [Related]  

  • 20. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.
    JAMA; 1998 Apr 22-29; 279(16):1265-72. PubMed ID: 9565006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.